shutterstock_1569359980_sundry_photography
Sundry Photography / Shutterstock.com
2 April 2020BiotechnologySarah Morgan

Gilead fails to overturn $752m BMS patent verdict

A court has rejected  Gilead’s attempt to overturn a $752 million verdict in a patent dispute with  BMS’ Juno Therapeutics over CAR-T therapies.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
4 June 2026   The deal gives Pfizer access to 12 early-stage oncology programmes and marks the latest in a growing wave of high-value licensing agreements between Big Pharma and Chinese biotechs.
Biotechnology
8 April 2026   The acquisition of Munich-based biotech gives Gilead ownership of proprietary ADCs tech at a time when pharma and biotech companies are racing to secure next-generation cancer treatments.
Biotechnology
7 April 2026   On World Health Day 2026, despite data trending in the right direction, systemic barriers continue to limit female inventors—and women's health is suffering.